The study, which began in mid-March, is the first to test the malaria drug as a preventative measure. Researchers enrolled 800 people in the U.S. and Canada, most of which were front-line healthcare workers, who had been exposed to someone with COVID-19.
Participants received either hydroxychloroquine or a vitamin placebo for five days and were then monitored for two weeks. The study was double-blinded, so neither the participants nor the researchers knew which medication was being received.
More articles on pharmacy:
Eli Lilly testing COVID-19 drug derived from survivor blood
Researchers testing several heart, anti-platelet drugs for COVID-19 patients
4 pharmacy leaders on mitigating drug shortages during a pandemic
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
